Our investigator-initiated clinical trials span many clinical settings, including surgery or chemoradiotherapy as primary treatment, as well as recurrent or metastatic disease. Clinical trials are led by head and neck surgeons, medical oncologists, and radiation oncologists, demonstrating the depth of multidisciplinary collaborations and the balanced development of the HNCP.
- A phase I clinical study was conducted combining inhibition of epidermal growth factor receptor (EGFR) with an anti-EGFR monoclonal antibody and Src family kinases (SFK) with dasatinib in solid malignancies. Dasatinib 150 mg once daily plus weekly cetuximab is recommended for phase II studies. Early-onset headache was ameliorated by starting dasatinib after cetuximab (Argiris et.al., Invest New Drugs. 2011 Sep 1).
- In a phase II clinical trial, HNCP investigators studied the effect of bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), to potentiate the activity of pemetrexed, a multitargeted antifolate, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Results show promising efficacy outcomes (Argiris et.al., J Clin Oncol. 2011 Mar 20;29(9):1140-5).
| Ferris, Robert L., MD, PhD, FACS
|Johnson, Jonas, MD, FACS|
|Gibson, Michael, MD
|Mountz, James, MD, PhD
|Gooding, William, MS
|Normolle, Daniel, PhD
|Grandis, Jennifer, MD, FACS
|Parwani, Anil, MD, PhD
|Heron, Dwight, MD, FACRO|